Wednesday September 23, 2020
Preconference Events
Toronto III

7:30-4:15  Resident Refresher Course
Facilitator:  Jennifer Croke

7:30-8:00  Breakfast and Registration

8:00-8:15  Welcome and Introduction

8:15-9:00  Management of Oropharyngeal Cancers
Anthony Nichols

9:00-9:45  Liver
   tbd

9:45-10:05 Refreshment Break

10:05-10:50  SBRT Spine
   tbd

10:50-11:35  Clinical Trials
   tbd

11:30-1:00  Lunch/Resident Meeting

1:00-1:45  Gyne
   tbd

1:45-2:15  Financial Planning
   tbd

2:15-2:45  Presentation Skills
Jennifer Croke

2:45-3:00  Break

3:00-4:30  Planning Evaluation
   tbd

4:30-4:35  Closing Remarks
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:45-6:00</td>
<td>Resident Career Counselling Social Event</td>
<td>tbd</td>
</tr>
<tr>
<td>12:00-4:00</td>
<td>CROF Public Engagement</td>
<td>Toronto I</td>
</tr>
<tr>
<td>5:30-8:30</td>
<td>CARO Board Meeting</td>
<td>Governor General, 2nd floor</td>
</tr>
</tbody>
</table>
Thursday September 24, 2020

7:00-8:00  Breakfast and Registration  
          Ballroom Foyer

7:00-8:00  Meet and Greet  
          Governor General, 2nd floor

8:00-8:15  Welcome and Introductions  
          Toronto I/II  
          Meredith Giuliani, Corinne Doll, CAMRT Rep

8:15-9:45  Theme Symposium  
          The COVID-19 Pandemic and Beyond: Lessons for Radiation Oncology  
          Facilitator:
          xx  
          xx

9:45-10:30  Refreshment Break

10:30-11:30  CARO Lecture  
           Introduction:
           Title:  
           Sandra Turner

11:30-12:30  Resident Competition

1  INTERIM ANALYSIS OF A PHASE II MULTI-INSTITUTION RANDOMIZED, PLACEBO-CONTROLLED TRIAL, THE PREMIUM TRIAL (PREVENTION OF METABOLIC SYNDROME AND INCREASED WEIGHT USING METFORMIN CONCURRENT TO ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALLY ADVANCED ADENOCARCINOMA OF THE PROSTATE).  
Karan Paul Sanghera

2 ACUTE AND SUBACUTE GASTROINTESTINAL AND GENITOURINARY TOXICITY PROFILES OF METFORMIN VERSUS PLACEBO PLUS PROSTATE AND PELVIC RADIOTHERAPY FOR THE MANAGEMENT OF HIGH RISK PROSTATE CANCER: INTERIM TOXICITY RESULTS OF A DOUBLE-BLINDED, MULTICENTER, PHASE II RANDOMIZED CONTROLLED TRIAL  
Megan McDonald

3 LONG TERM BIOCHEMICAL CONTROL OF A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS TREATED WITH INTERSTIAL BRACHYTHERAPY VERSUS RADICAL PROSTATECOMY  
Gordon Locke

4 PRIMARY ANALYSIS OF A PHASE II STUDY OF METASTASIS-DIRECTED ABLATIVE THERAPY TO PSMA (18F-DCFPLY) PET-MR/CT DEFINED OLIGORECURRENT PROSTATE CANCER  
Rachel Glicksman

5 IS THE TOXICITY OF BREAST RADIOTHERAPY HIGHER IN PATIENTS WITH COLLAGEN VASCULAR DISEASE? A SYSTEMATIC REVIEW OF THE LITERATURE  
Wei Liu

6 HYPERFRACTIONATED POSTMASTECTOMY RADIOTHERAPY IN PATIENTS WITH IMMEDIATE BREAST RECONSTRUCTION: INSTITUTIONAL OUTCOMES  
Natalie Logie
12:30-2:30 Lunch/Industry Symposium/Committee Meetings

Symposium – Varian?
Governor General, 2nd floor

2:30-4:00 Education Session 1
Tom Thomson
Stereotactic Radioablation for Ventricular Tachycardia
Joanne Alfieri, Martin Bernier, Tarek Hijal, Neil Kopek, Piotr Pater, Jordan Stosky, Gabriela Stroian

Objectives: By the end of this session, the participants will be able to:
• Describe the basic radiation physics and radiobiology relevant to ablative radiotherapy to the heart.
• Explain invasive and non-invasive ways to map ventricular tachycardia (VT).
• Review preclinical data and clinical data as a rationale for non-invasive radioablation of VT.
• Evaluate a plan for stereotactic radioablation of a VT target.
• Strategize on developing a trial for stereotactic radioablation for VT.

Education Session 2
Carmichael Jackson
Initiatives Improving Radiotherapy Standardization: Paving the Way to Improved Quality of Care and Big Data Research
Amanda Caissie, John Kildea, Michael Milosevic, Michael Brundage, Kim Rans

Objectives: By the end of this session, the participants will be able to:
• Increase awareness of recent consensus guidelines from international organizations such as AAPM and ASTRO promoting standardized technical language for RT.
• Discuss the potential clinical benefits of RT standardization, including but not limited to increased peer review efficiency and availability of patient reported outcomes for point of care clinical use.
• Discuss the potential Big Data research benefits of RT standardization, with examples provided from several Canadian PRO/Big Data “early adopters”.
• Review CPQR’s recently developed guidance documents related to Big Data (Guidance on the Use of Common Nomenclature in Canadian Radiation Treatment Programs) and PRO (Guidance on the Use of Patient Reported Outcomes for Canadian Radiation Treatment Programs).
• Discuss change management approaches to facilitate implementation of such initiatives locally.

4:00-5:00 Posters

5:00-6:15 Mentoring Session

7:00 Welcome Reception – The Fifth Social Club
225 Richmond St. W
https://fifthsocialclub.thefifth.com/
Friday September 25, 2020

7:0-8:00 Breakfast Symposium
Governor General, 2nd floor

7:00-8:00 Breakfast and Registration/Yoga

8:00-9:00 Gold Medal and Gordon Richards Lecture
Introductions:
xx
Lisa Barbera

9:00-10:15 Plenary Abstracts

7 RESECTION MARGIN STATUS AND RADIATION BOOST TO SURGICAL CAVITY AFTER BREAST CONSERVING SURGERY, A PATTERN-OF-PRACTICE STUDY IN BRITISH COLUMBIA
Hamid Raziee

8 STEREOTACTIC ABLATIVE RADIOTHERAPY FOR THE COMPREHENSIVE TREATMENT OF OLIGOMETASTATIC CANCERS: LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL
David Palma

9 A PHASE II MULTI-CENTRE TRIAL OF STEREOTACTIC RADIOTHERAPY FOR OLIGOPROGRESSION IN METASTATIC KIDNEY CANCER PATIENTS RECEIVING TYROSINE KINASE INHIBITOR THERAPY
Patrick Cheung

10 SALVAGE LOW DOSE RATE PROSTATE BRACHYTHERAPY: CLINICAL OUTCOMES OF A PHASE II TRIAL FOR LOCAL RECURRENCE AFTER EXTERNAL BEAM RADIOTHERAPY (NRG/RTOG 0526)
Juanita Crook

10:15-11:00 Refreshment Break

11:00-12:30 Education Session 3
Proton Therapy for Canadian Radiation Health Care Providers: A Primer
Derek Tsang, Samir Patel, Tim Craig, Amy Parent, Mike Holwell, Andrea Lo, Sonia Skamene

Objectives: By the end of this session, the participants will be able to:
• Discuss status of proton therapy (PT) utilization across Canada, what makes a good case for PT, dosimetric considerations, practical barriers to referral, and be aware of how to make a referral with one’s provincial ministry of health.

Education Session 4
Setting up an Oligo-Metastasis Program
Aisling Barry, JP Bissonnette, Richard Moore, Matthew Chan, Meredith Giuliani, Rebecca Wong, Joanna Javor

Objectives: By the end of this session, the participants will be able to:
• Understand the nuances with establishing a oligo-metastasis clinical referral pathway.
• Understand practical planning issues associated with oligo-metastatic disease.
• Consider potential complex plan reviews and quality assurance issues.
• Review treatment delivery and IGRT challenges in multi-site oligo-metastatic disease.
12:30-2:30 Lunch/Industry Symposium/Committee Meetings

Industry Symposium - AstraZeneca
Governor General, 2nd floor

2:30-3:30 Jean Roy Lecture
Introduction:

Title:
Conrad Falkson

3:30-4:30 CBG Oral Session

11 MRI-DEFINED TREATMENT MARGINS IN LDR PROSTATE BRACHYTHERAPY
Jim Rose

12 AN UPDATED ANALYSIS OF SURVIVAL ENDPOINTS FOR ASCENDE-RT, A RANDOMIZED TRIAL COMPARING A LOW-DOSE-RATE BRACHYTHERAPY BOOST TO A DOSE-ESCALATED EXTERNAL BEAM BOOST FOR HIGH- AND INTERMEDIATE-RISK PROSTATE CANCER
Justin Oh

13 COST-UTILITY ANALYSIS OF RADIATION STRATEGIES IN THE MANAGEMENT OF INTERMEDIATE-RISK PROSTATE CANCER
Joelle helou

14 17 YEARS EXPERIENCE OF EBRT PLUS HDR BRACHYTHERAPY BOOST IN HIGH RISK LOCALIZED PROSTATE CANCER PATIENTS: A COMPETING RISKS ANALYSIS
Damien Carignan

15 ANALYSIS OF PSA KINETICS AND LATE TREATMENT RELATED TOXICITY IN A PHASE 2 RANDOMIZED PILOT STUDY COMPARING HIGH DOSE RATE BRACHYTHERAPY AND LOW DOSE RATE BRACHYTHERAPY AS MONOTHERAPY IN LOCALIZED PROSTATE CANCER
Thomas Reynaud

16 DEFORMABLE IMAGE REGISTRATION-ENABLED CUMULATIVE TOTAL (DIRECT) DOSE ADAPTATION IN PROSTATE RADIOTHERAPY
Aran Kim

4:30-5:30 AGM

5:45-6:45 CROF Fun Run/Walk

7:30-11:00 CARO Games Night
The Ballroom
145 John St.
www.theballroom.ca
Saturday September 26, 2020

7:00-8:00 Breakfast Symposium
Governor General, 2nd Floor

7:00-8:00 Breakfast and Registration/Yoga

8:00-9:00 Fellow Competition

17 A PROGNOSTIC GENE EXPRESSION SIGNATURE FOR WOMEN WITH CERVICAL CANCER RECEIVING CURATIVE INTENT TREATMENT
Jelena Lukovic

18 STEREOTACTIC BODY RADIATION THERAPY FOR MEDIASTINAL AND HILAR LYMPH NODE METASTASES: A SINGLE-INSTITUTIONAL REVIEW OF CLINICAL OUTCOMES
Jeevin Shahi

19 EFFECTIVENESS OF STEREOTACTIC BODY RADIATION THERAPY (SBRT) FOR OLIGOMETASTATIC NON-SPINE BONE LESIONS: AN INTERNATIONAL CONSORTIUM STUDY
Hanbo Chen

20 RADIATION THERAPY ALONE VERSUS RADIATION THERAPY WITH HORMONAL THERAPY FOR WOMEN WITH EARLY STAGE BREAST CANCER: A POPULATION-BASED STUDY
Tina (Wanting) Zhang

21 COMPARISON OF ACUTE TOXICITIES IN PATIENTS WITH PROSTATE CANCER TREATED WITH HIGH DOSE RATE VERSUS LOW DOSE RATE BRACHYTHERAPY BOOST
Arun Elangovan

22 NEO-ADJUVANT TREATMENT FOR MANAGEMENT OF STAGE IV RECTAL CANCERS WITH OLIGOMETASTATIC DISEASE AT PRESENTATION
Aswin Abraham

9:00-10:00 Oral Session 1 – Applied Technology and Physics

23 MR-LINAC RADIOTHERAPY: EXPERIENCE, DATA COLLECTION AND IMAGING IN YEAR ONE
Brian Keller

24 PRELIMINARY EXPERIENCE WITH MRI-GUIDED ONLINE ADAPTIVE SBRT FOR LIVER ON AN MR-LINAC SYSTEM
Teo Stanescu

25 IMPLEMENTATION OF DEEP LEARNING-BASED AUTO-SEGMENTATION FOR RADIOTHERAPY PLANNING STRUCTURES: A MULTI-CENTER WORKFLOW STUDY
Jordan Wong

26 AUTOMATED MACHINE-LEARNING RADIOTHERAPY PLANNING FOR PEDIATRIC AND ADULT BRAIN TUMOURS
Grace Tsui

27 EVALUATING DOSIMETRIC IMPACT OF INTRA-FRACTION MOTION FOR ULTRA-HYPO-FRACTIONATED PROSTATE PATIENTS TREATED ON THE MR-LINAC
Jennifer Dang

28 DEFORMABLE REGISTRATION FOR EVIDENCE-BASED PTV MARGINS IN LUNG SABR: CAN MODERN TECHNIQUES FACILITATE REDUCTION IN PTV MARGINS WHILE MAINTAINING IGTV COVERAGE?
Katie Jasper
9:00-10:00    Oral Session 2 – Population Science

29 CARING FOR THE CAREGIVERS: AN ENVIRONMENTAL SCAN OF CHILDCARE PROGRAMS FOR PATIENTS WITH CANCER
Paris Ann Ingledew

30 IS INTERMITTENT ANDROGEN DEPRIVATION THERAPY AN UNDERUTILIZED STRATEGY FOR MANAGEMENT OF RELAPSED, NON-METASTATIC, CASTRATION SENSITIVE PROSTATE CANCER? - A POPULATION-BASED ASSESSMENT OF A PROVINCIAL CANCER PROGRAM
Bryan Janzen

31 PATIENT PREFERENCES FOR HYPOFRACTIONATED RADIOTHERAPY TO TREAT LOCALIZED PROSTATE CANCER: A DISCRETE CHOICE EXPERIMENT
Samantha Sigurdson

32 RADIATION AND/OR ENDOCRINE THERAPY? RECURRENCE AND SURVIVAL OUTCOMES IN WOMEN OVER 70 WITH EARLY BREAST CANCER AFTER BREAST CONSERVING SURGERY
Hannah Dahn

33 GEOGRAPHIC ACCESSIBILITY TO RADIOTHERAPY IN CANADA FOR INDIGENOUS POPULATIONS: HIGHLIGHTING THE INEQUITIES
Jessica Chan

34 IMPROVING THE QUALITY OF PATIENT REPORTED OUTCOMES IN RANDOMIZED CLINICAL TRIALS BY MINIMIZING MISSING DATA
Michael Palmer

10:00-10:30    Refreshment Break

10:30-12:00    CARO-ESTRO Symposium
GIRO
Mary Gospodarowicz, Yolande Lievens

12:00-1:00    ASRT Lecture
Introduction:
Quantitative Imaging in Radiation Therapy: What's Our Role?
Stacy Anderson

1:00-1:30    Refreshment Break

1:30-2:30    Oral Session 3 – Stereotactic Radiosurgery

35 IMAGING-BASED LOCAL CONTROL RATES FOR "RADIORESISTANT" SPINAL METASTASES FOLLOWING SPINE STEREOTACTIC BODY RADIOTHERAPY USING PROSTATE CANCER AS THE "RADIOSENSITIVE" REFERENCE
Kang Liang Zeng

36 SURGERY VS SBRT FOR EARLY-STAGE NSCLC IN OCTOGENARIANS AND NONAGENARIANS: AN OVERALL SURVIVAL DIFFERENCE?
Ana-Maria Misariu

37 STEREOTACTIC RADIOSURGERY FOR SMALL CELL LUNG CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Eric Nguyen

38 STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOMETASTATIC PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE TRIALS
Michael Yan

39 IMPACT OF SMOKING STATUS AND PACK YEAR HISTORY ON OUTCOMES OF EARLY STAGE NON-SMALL CELL LUNG CANCERS TREATED WITH STEREOTACTIC ABLATIVE RADIOTHERAPY
Jack Zheng
40 PATTERNS OF FAILURE IN EXTRA-CRANIAL OLIGOMETASTATIC PATIENTS TREATED WITH DEFINITIVE STEREOTACTIC BODY RADIOTHERAPY (SBRT)  
ian poon

1:30-2:30 Oral Session 4 – Education and Survivorship

41 DO COORDINATED KNOWLEDGE TRANSLATION CAMPAIGNS PERSUADE RADIATION ONCOLOGISTS TO UTILIZE SINGLE FRACTION RADIOTHERAPY OVER MULTIPLE FRACTION RADIOTHERAPY FOR BONE METASTASES?  
Shaheer Shahhat

42 FACTORS THAT PROMOTE MEDICAL STUDENT INTEREST IN RADIATION ONCOLOGY: A SURVEY OF CANADIAN RADIATION ONCOLOGY RESIDENTS  
Maryam Dosani

43 EVALUATION OF A 3D-PRINTED-HEAD SIMULATION TECHNIQUE FOR TEACHING FLEXIBLE NASOPHARYNGOSCOPY TO RADIATION ONCOLOGY RESIDENTS  
Chris Goodman

44 ALIGNMENT OF REGULATORY EXAMINATIONS AND PUBLIC HEALTH PRIORITIES: EXPLORING THE REPRESENTATION OF CANCER IN THE MCCQE-1  
Marissa Sherwood

45 PATIENT-REPORTED OUTCOMES, PHYSICIAN-REPORTED TOXICITY AND DOSIMETRY IN CERVICAL CANCER PATIENTS TREATED WITH CHEMO-RADIATION AND MR-GUIDED BRACHYTHERAPY  
Jennifer Croke

46 EXAMINING CANNABIS USAGE AND CANNABIS-RELATED INFORMATION SOURCING FOR DISEASE MANAGEMENT IN CLINICAL ONCOLOGY  
James Ddamba

2:30-3:30 Oral Session 5 – Breast Cancer and Palliative Care

47 5 YEAR LONGITUDINAL ANALYSIS OF MYOCARDIAL PERFUSION SCINTIGRAPHY POST RADIOTHERAPY USING SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT). PROSPECTIVE COMPARISON OF LONG TERM CARDIAC FUNCTION OF PATIENTS PARTICIPATED IN A PHASE III RANDOMIZED STUDY OF BREAST CONSERVING SURGERY AND RADIOTHERAPY  
Karan Paul Sanghera

48 NEW ASPECTS REGARDING THE RADIATION OF PARTIAL- AND WHOLE BREAST IN EARLY STAGE BREAST CANCER  
Edwin Boelke

49 AXILLARY LYMPH NODE COVERAGE IN BREAST CANCER PATIENTS TREATED WITH ADJUVANT RADIATION USING HIGH TANGENT TECHNIQUE: BC CANCER KELOWNA EXPERIENCE  
Ajhmair Lali

50 TRIPLE NEGATIVE BREAST CANCER IS ASSOCIATED WITH INFERIOR PATIENT REPORTED OUTCOMES FOLLOWING PALLIATIVE RADIOTHERAPY FOR BONE METASTASES  
Daegan Sit

51 A PHASE III RANDOMIZED TRIAL OF PALLIATIVE RADIATION FOR ADVANCED CENTRAL LUNG TUMORS WITH INTENTIONAL AVOIDANCE OF THE ESOPHAGUS (PROACTIVE)  
Alex Louie

52 FUTILE RADIOTHERAPY AT THE END OF LIFE: DETERMINING PREDICTORS OF PALLIATIVE RADIOTHERAPY NOT TAKEN TO COMPLETION  
Siddhartha Goutam
2:30-3:30  Oral Session 6 – A Mix

53 UTILITY OF POST-TREATMENT PET IN HPV ASSOCIATED OROPHARYNGEAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Pencilla Lang

54 RE-IRRADIATION FOR RECURRENT CRANIOPHARYNGIOMA

Sarah Foran

55 THE RATE OF PROSTATIC INVOLVEMENT IN MEN TREATED WITH RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER

BENJAMIN ROYAL-PREYRA

56 OUTCOMES FROM A SINGLE INSTITUTION COHORT OF 248 PATIENTS WITH STAGE I-III ESOPHAGEAL CANCER TREATED WITH RADIOTHERAPY

Mark Niglas

57 RED BLOOD CELL TRANSFUSION PRACTICES FOR CERVIX CANCER PATIENTS UNDERGOING RADIOTHERAPY: AN INTERNATIONAL DELPHI CONSENSUS STUDY

SONDOS ZAYED

58 PATTERNS OF PRACTICE AND CLINICAL OUTCOMES IN PATIENTS WITH VULVAR CARCINOMA

lama khoja

3:30-4:00  Awards and Closing Remarks

Poster Abstracts

#59-216